| dbo:abstract
|
- Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity). Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency. A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex. The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency. (en)
- Mecasermina (INN, nome commerciale Increlex) è un fattore di crescita insulino-simile (IGF-I) ricombinante umano, prodotto in Escherichia coli cioè in batteri che sono stati modificati mediante l’aggiunta del gene per l’IGF-1 umano. Il farmaco viene utilizzato per il trattamento a lungo termine del deficit di crescita nei bambini con deficit di IGF-I primario grave. Questo farmaco non deve essere confuso con mecasermina rinfabato (nome commerciale Iplex), che è una combinazione di ricombinante IGF-1 (rhIGF-1) umano e del fattore di crescita insulino-simile binding protein-3 (-3). L'IGFBP-3 serve per prolungare l'azione dell'IGF-1 nel corpo umano. (it)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 4299 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:drugbank
| |
| dbp:eliminationHalfLife
| |
| dbp:h
| |
| dbp:kegg
| |
| dbp:legalAu
| |
| dbp:legalCa
|
- Rx-only / Schedule D (en)
|
| dbp:legalUs
| |
| dbp:licenceEu
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pregnancyAu
| |
| dbp:routesOfAdministration
| |
| dbp:s
| |
| dbp:synonyms
|
- FK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1 (en)
|
| dbp:tradename
| |
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity). Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency. (en)
- Mecasermina (INN, nome commerciale Increlex) è un fattore di crescita insulino-simile (IGF-I) ricombinante umano, prodotto in Escherichia coli cioè in batteri che sono stati modificati mediante l’aggiunta del gene per l’IGF-1 umano. Il farmaco viene utilizzato per il trattamento a lungo termine del deficit di crescita nei bambini con deficit di IGF-I primario grave. (it)
|
| rdfs:label
|
- Mecasermina (it)
- Mecasermin (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:treatment
of | |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is dbp:treatment
of | |
| is foaf:primaryTopic
of | |
